PsychedelicNewsBreaks

ThursdaySep 29, 2022 11:00 am

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC Expands Insurance Coverage with Medicare for Ketamine Therapy Patients

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has become one of a few U.S.-based ketamine therapy providers to offer Medicare coverage to patients at eight KWC clinics across the country. Under Medicare, KWC is accepting a limited number of patients for ketamine infusion therapy at Chicago, Denver, Houston, Jacksonville, Minneapolis, Tucson, Salt Lake City and Seattle clinics. In addition, KWC is providing the FDA-approved SPRAVATO(R) esketamine treatment at Houston, Jacksonville and Seattle locations for patients meeting the criteria for insurance coverage. “At Ketamine…

Continue Reading

WednesdaySep 28, 2022 11:36 am

PsychedelicNewsBreaks – Universal Ibogaine Inc. (TSX.V: IBO) Featured in ‘Psychedelics Tonight’ Docuseries

Universal Ibogaine (TSX.V: IBO) (“UI”), a life sciences company with a mission to deliver medicalized ibogaine-centered addiction care, announced it has been featured in a documentary series, which was co-produced by Kyle Buller and Joe Moore of Psychedelics Today in partnership with ALTRD.TV. Entitled Psychedelics Tonight, the docuseries provides information on the history and future potential of several psychedelic compounds including iboga and ibogaine. The first episode of the series aired on Monday, Sept. 26, 2022. “We are excited to see a growing variety of media channels pick up the story of ibogaine, to help educate the public and the…

Continue Reading

TuesdaySep 27, 2022 3:24 pm

PsychedelicNewsBreaks – Awakening of Consciousness to Illuminate Vast Potential of Psychedelic Medicine

The Psychedelic Institute today announced that it is convening the first major psychedelic conference to be held in Los Angeles on Friday, Sept. 30. Slated to take place at the Founder’s Church of Religious Science, the Awakening of Consciousness will offer the public an opportunity to hear, meet and learn from 30 of the world's leading researchers, healers and activists working in the field of psychedelics and plant medicine. The event will feature 18 general session speakers, five panel discussions and seven participatory workshops. Experts will share insight on the vast potential of psychedelic medicine to heal trauma, addiction, depression,…

Continue Reading

TuesdaySep 27, 2022 2:29 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement for the license will provide access to large catalog of compounds that are complementary to Cybin’s preclinical assets and that strengthen the company’s drug-discovery and development platform to build future potential novel drug candidates. The agreement also supports Cybin’s broad intellectual property portfolio of innovative psychedelic-based molecules. According to…

Continue Reading

TuesdaySep 27, 2022 11:39 am

PsychedelicNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Uplisting to Nasdaq Capital Market, Pricing of $5M Public Offering

Silo Pharma (NASDAQ: SILO) (formerly OTCQB: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced pricing of an underwritten public offering of 1,000,000 shares of its common stock at a price to the public of $5.00 per share. Silo Pharma expects $5,000,000 in gross proceeds from the offering and intends to use the net proceeds for product development, marketing, working capital and general corporate purposes. In addition, a portion of the proceeds may also be used for acquisitions of complementary businesses, technologies or other assets. As a result of the offering, the company’s…

Continue Reading

MondaySep 26, 2022 10:55 am

PsychedelicNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Announces Methodical Expansion of Its IP Portfolio

Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced the filing of two new provisional patent applications. According to the update, one application, #63/405,786, is for the use of psilocybin for the treatment of patients with fibromyalgia and the other, #63/375,305, expands the IP related to the company’s development of TRP-8803. “Tryp is taking an innovative approach to expand treatment alternatives for patients suffering from nociplastic pain and eating disorders who haven’t had success with currently approved drugs,” said Jim Gilligan, chief executive officer of Tryp…

Continue Reading

FridaySep 23, 2022 1:28 pm

PsychedelicNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) Announces Closing Under Share Subscription Agreement, Appointment of New CFO

Mydecine (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA), is a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD. The company today announced that, in connection with its previously disclosed common share subscription agreement with a third-party investor dated Aug. 26, 2022, and the subsequent filing of a shelf prospectus supplement in connection therewith on Sept. 7, 2022, it has closed the second tranche of the first issuance under the subscription agreement. Mydecine also announced the appointment of John Ross as its chief financial officer.…

Continue Reading

ThursdaySep 22, 2022 12:06 pm

PsychedelicNewsBreaks – Delic Holdings Corp.’s (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) KWC, VA-CCN Collaborate to Expand Access to SPRAVATO(R) Treatments

Ketamine Wellness Centers (“KWC”), the largest ketamine therapy provider in the U.S. and a subsidiary of Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), has expanded its partnership with the Veterans Administration Community Care Network (“VA-CCN”) to cover SPRAVATO(R) treatments at select clinics. VA-CCN patients experiencing treatment-resistant depression with prior authorization from the VA-CCN will now have access to treatments at the following KWC clinics: Mesa, Tucson, Phoenix, Denver, Seattle, Reno, Las Vegas, Houston and Dallas. “KWC works every day to provide the best, most effective treatments to those who need them most and our veterans, who suffer from various…

Continue Reading

WednesdaySep 21, 2022 12:11 pm

PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences

Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, Ethics & Business Event in Haarlem, Amsterdam. The announcement includes further details on additional conferences and the participation schedule for Drysdale and additional members of Cybin’s management team in panel discussions and presentations. The additional events include the Interdisciplinary Conference on Psychedelic Research, Sept. 22-24,…

Continue Reading

TuesdaySep 20, 2022 1:43 pm

PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug development. The milestones were key in moving Cybin’s psychedelic programs from lab to clinic and have enabled the company to discover potential new drug formulations and delivery methods as well as create clinical protocols for psychedelic compounds and support clinical-stage development of CYBN’s proprietary CYB003…

Continue Reading